<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03106792</url>
  </required_header>
  <id_info>
    <org_study_id>16HHHB</org_study_id>
    <nct_id>NCT03106792</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Effectiveness of Hairfinity on Improving Hair Health and Rate of Growth</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, 4-arm Parallel Study to Evaluate the Effectiveness of Hairfinity on Improving Hair Health and Rate of Growth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brock Beauty Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KGK Science Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brock Beauty Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary outcome of the study is the effect of Hairfinity vs. Placebo on the rate of&#xD;
      distal hair growth, assessed using Trichoscan HD, in healthy female adults from baseline to&#xD;
      day 90 (end of study).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 24, 2017</start_date>
  <completion_date type="Actual">June 29, 2018</completion_date>
  <primary_completion_date type="Actual">June 29, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of distal hair growth</measure>
    <time_frame>90 days</time_frame>
    <description>assessed using Trichoscan HD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in number of shed hair strands</measure>
    <time_frame>90 days</time_frame>
    <description>assessed using the standardized wash test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean diameter of hair fibers</measure>
    <time_frame>90 days</time_frame>
    <description>assessed using Trichoscan HD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hair density</measure>
    <time_frame>90 days</time_frame>
    <description>assessed using Trichoscan HD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of terminal and vellus hairs</measure>
    <time_frame>90 days</time_frame>
    <description>assessed using Trichoscan HD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the percent of hairs in the anagen and telogen phases</measure>
    <time_frame>90 days</time_frame>
    <description>assessed using Trichoscan HD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hair quality parameters</measure>
    <time_frame>90 days</time_frame>
    <description>assessed by a dermatologist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hair quality</measure>
    <time_frame>90 days</time_frame>
    <description>assessed by a dermatologist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hair quality</measure>
    <time_frame>90 days</time_frame>
    <description>assessed with self-assessment questionnaires</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal vital signs</measure>
    <time_frame>90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal complete blood panel</measure>
    <time_frame>90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal electrolytes</measure>
    <time_frame>90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal kidney function panel</measure>
    <time_frame>90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal liver function panel</measure>
    <time_frame>90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>90 days</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Hairfinity #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hairfinity #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hairfinity #3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hairfinity #1</intervention_name>
    <description>Main Hairfinity formulation</description>
    <arm_group_label>Hairfinity #1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hairfinity #2</intervention_name>
    <description>Variation to main formulation</description>
    <arm_group_label>Hairfinity #2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hairfinity #3</intervention_name>
    <description>Variation to main formulation</description>
    <arm_group_label>Hairfinity #3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>No active ingredients</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female 18-50 years of age (inclusive)&#xD;
&#xD;
          2. Subject is not of child bearing potential. Defined as females who have had a&#xD;
             hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural&#xD;
             or surgically with &gt; 1 year since last menstruation).&#xD;
&#xD;
             OR&#xD;
&#xD;
             Female subject of childbearing potential must agree to use a medically approved method&#xD;
             of birth control and have a negative urine pregnancy test result. Acceptable methods&#xD;
             of birth control include:&#xD;
&#xD;
               -  Hormonal contraceptives including oral contraceptives, hormone birth control&#xD;
                  patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable&#xD;
                  contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)&#xD;
&#xD;
               -  Intrauterine devices&#xD;
&#xD;
               -  Vasectomy of partner&#xD;
&#xD;
               -  Double Barrier Method&#xD;
&#xD;
               -  Non-heterosexual lifestyle&#xD;
&#xD;
          3. Fitzpatrick skin type of I-V (See appendix 3)&#xD;
&#xD;
          4. Willing to maintain the colour of and style of the hair cut for the duration of the&#xD;
             study&#xD;
&#xD;
          5. Willing to maintain shampooing frequency and general hair regime for the duration of&#xD;
             the study&#xD;
&#xD;
          6. Willing to not cut hair for the duration of the study&#xD;
&#xD;
          7. Willing to have area of hair prepped for Trichoscan analysis&#xD;
&#xD;
          8. Healthy as determined by laboratory results, medical history, and physical exam&#xD;
&#xD;
          9. Subjects must agree to comply with study procedures&#xD;
&#xD;
         10. Has given voluntary, written, informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant, breastfeeding, or planning to become pregnant during the&#xD;
             course of the trial.&#xD;
&#xD;
          2. Women who have begun hormonal birth control or hormone replacement within 6 months of&#xD;
             randomization&#xD;
&#xD;
          3. Subjects taking natural health products, including multi-vitamins, botanicals and&#xD;
             other nutraceuticals, within 2 weeks of randomization and for the duration of the&#xD;
             study&#xD;
&#xD;
          4. Subjects with Fitzpatrick scores over V, which stems from the sensitivity of the&#xD;
             testing method (requires a degree of color contrast when evaluating hair relative to&#xD;
             skin)&#xD;
&#xD;
          5. Subjects having underwent a form of treatment for thinning hair, including&#xD;
             prescription drugs or light therapy within 6 months of randomization&#xD;
&#xD;
          6. Medical history of diagnosed alopecia and/or trichotillomania (compulsive hair&#xD;
             pulling). Medical history may be assessed by the Qualified Investigator&#xD;
&#xD;
          7. Subjects currently using hair extensions&#xD;
&#xD;
          8. Subjects with psoriasis or any active dermatological condition of the scalp at&#xD;
             randomization that in the opinion of the qualified investigator would interfere with&#xD;
             the clinical evaluations&#xD;
&#xD;
          9. Medical history of thyroid disorders or with TSH levels outside the normal range&#xD;
             (0.4-4.5 Â±0.05) as assessed by the Qualified Investigator&#xD;
&#xD;
         10. Unstable medical condition as determined by qualified investigator&#xD;
&#xD;
         11. Clinically significant abnormal lab results at screening will be assessed by the&#xD;
             Qualified Investigator&#xD;
&#xD;
         12. History, or current diagnosis of any cancer (except for successfully treated basal&#xD;
             cell carcinoma in an area other than the scalp) diagnosed less than 5 years prior to&#xD;
             screening. Subjects with cancer in full remission more than 5 years of diagnosis are&#xD;
             acceptable.&#xD;
&#xD;
         13. Alcohol abuse or drug abuse within the past 6 months&#xD;
&#xD;
         14. Consumption of greater than 2 standard alcoholic drinks per day&#xD;
&#xD;
         15. Use of medicinal marijuana&#xD;
&#xD;
         16. Participation in a clinical research trial within 30 days prior to randomization&#xD;
&#xD;
         17. Allergy or sensitivity to study product and/or it's ingredients&#xD;
&#xD;
         18. Individuals who are cognitively impaired and/or who are unable to give informed&#xD;
             consent&#xD;
&#xD;
         19. Any other condition which in the Investigator's opinion may adversely affect the&#xD;
             subject's ability to complete the study or its measures or which may pose significant&#xD;
             risk to the subject (e.g. cardiovascular, renal, lung, diabetes, psychiatric illness,&#xD;
             bleeding disorders etc)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tetyana Pelipyagina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGK Science Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>April 4, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2017</study_first_posted>
  <last_update_submitted>July 9, 2018</last_update_submitted>
  <last_update_submitted_qc>July 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

